Tags

Type your tag names separated by a space and hit enter

Detection and identification of antinuclear antibodies (ANA) in a large and consecutive cohort of serum samples referred for ANA testing.
Ann Rheum Dis. 2001 Dec; 60(12):1131-6.AR

Abstract

OBJECTIVE

To provide data on (a) the probability of detecting antinuclear antibodies (ANA) in a large and consecutive cohort of serum samples referred for ANA testing and (b) the probability of detecting more specific antinuclear reactivities (anti-DNA and anti-extractable nuclear antigens (anti-ENA)) in serum samples with a positive screening test (indirect immunofluorescence on HEp-2 cells).

METHODS

Serum samples from 10 550 consecutive patients sent to the laboratory for ANA detection were analysed. In ANA positive serum samples (23.5% of referred serum samples), ANA were identified by indirect immunofluorescence on Crithidia, by immunodiffusion, and by line immunoassay. Because anti-SSA antibodies were the most frequently identified ANA, sensitively detected by line immunoassay, additional immunoassays were developed to confirm the specificity of the line immunoassay result.

RESULTS

At least one fine reactivity could be identified in 21.1% of ANA positive serum samples: anti-dsDNA in 3.2%; anti-ENA (anti-SSA 10.5%, anti-SSB 6.7%, anti-RNP 2.7%, anti-Sm 1.8%, anti-Scl70 1.2%, anti-Jo-1 0.2%) in 15.8%, rRNP and anti-Cenp-B in respectively 0.5% and 4.0%. Multiple reactivities were found in 7.9%. For anti-ENA antibodies, line immunoassay was more sensitive than immunodiffusion (15.4% v 7.7%; p<0.0001). The sensitive detection of anti-SSA antibodies by line immunoassay was confirmed by additional assays.

CONCLUSIONS

The data from this analysis are useful in estimating the probabilities of detecting specific ANA. Line immunoassay was shown to be a sensitive test for the detection of anti-ENA antibodies.

Links

PMC Free PDF
PMC Free Full Text
FREE Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Peene I
Department of Rheumatology, Ghent University Hospital, Belgium.
Meheus L
No affiliation info available
Veys EM
No affiliation info available
De Keyser F
No affiliation info available

MeSH

Antibodies, AntinuclearAntibody SpecificityAntigens, NuclearAutoantigensBiomarkersCohort StudiesConnective Tissue DiseasesDNA-Binding ProteinsFluorescent Antibody Technique, IndirectHumansImmunoassayImmunodiffusionNuclear Proteins

Pub Type(s)

Journal Article

Language

eng

PubMed ID

11709455

Citation

Peene, I, et al. "Detection and Identification of Antinuclear Antibodies (ANA) in a Large and Consecutive Cohort of Serum Samples Referred for ANA Testing." Annals of the Rheumatic Diseases, vol. 60, no. 12, 2001, pp. 1131-6.
Peene I, Meheus L, Veys EM, et al. Detection and identification of antinuclear antibodies (ANA) in a large and consecutive cohort of serum samples referred for ANA testing. Ann Rheum Dis. 2001;60(12):1131-6.
Peene, I., Meheus, L., Veys, E. M., & De Keyser, F. (2001). Detection and identification of antinuclear antibodies (ANA) in a large and consecutive cohort of serum samples referred for ANA testing. Annals of the Rheumatic Diseases, 60(12), 1131-6.
Peene I, et al. Detection and Identification of Antinuclear Antibodies (ANA) in a Large and Consecutive Cohort of Serum Samples Referred for ANA Testing. Ann Rheum Dis. 2001;60(12):1131-6. PubMed PMID: 11709455.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Detection and identification of antinuclear antibodies (ANA) in a large and consecutive cohort of serum samples referred for ANA testing. AU - Peene,I, AU - Meheus,L, AU - Veys,E M, AU - De Keyser,F, PY - 2001/11/16/pubmed PY - 2002/1/5/medline PY - 2001/11/16/entrez SP - 1131 EP - 6 JF - Annals of the rheumatic diseases JO - Ann Rheum Dis VL - 60 IS - 12 N2 - OBJECTIVE: To provide data on (a) the probability of detecting antinuclear antibodies (ANA) in a large and consecutive cohort of serum samples referred for ANA testing and (b) the probability of detecting more specific antinuclear reactivities (anti-DNA and anti-extractable nuclear antigens (anti-ENA)) in serum samples with a positive screening test (indirect immunofluorescence on HEp-2 cells). METHODS: Serum samples from 10 550 consecutive patients sent to the laboratory for ANA detection were analysed. In ANA positive serum samples (23.5% of referred serum samples), ANA were identified by indirect immunofluorescence on Crithidia, by immunodiffusion, and by line immunoassay. Because anti-SSA antibodies were the most frequently identified ANA, sensitively detected by line immunoassay, additional immunoassays were developed to confirm the specificity of the line immunoassay result. RESULTS: At least one fine reactivity could be identified in 21.1% of ANA positive serum samples: anti-dsDNA in 3.2%; anti-ENA (anti-SSA 10.5%, anti-SSB 6.7%, anti-RNP 2.7%, anti-Sm 1.8%, anti-Scl70 1.2%, anti-Jo-1 0.2%) in 15.8%, rRNP and anti-Cenp-B in respectively 0.5% and 4.0%. Multiple reactivities were found in 7.9%. For anti-ENA antibodies, line immunoassay was more sensitive than immunodiffusion (15.4% v 7.7%; p<0.0001). The sensitive detection of anti-SSA antibodies by line immunoassay was confirmed by additional assays. CONCLUSIONS: The data from this analysis are useful in estimating the probabilities of detecting specific ANA. Line immunoassay was shown to be a sensitive test for the detection of anti-ENA antibodies. SN - 0003-4967 UR - https://www.unboundmedicine.com/medline/citation/11709455/Detection_and_identification_of_antinuclear_antibodies__ANA__in_a_large_and_consecutive_cohort_of_serum_samples_referred_for_ANA_testing_ L2 - https://ard.bmj.com/lookup/pmidlookup?view=long&amp;pmid=11709455 DB - PRIME DP - Unbound Medicine ER -